Literature DB >> 7479205

Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.

H C Ko1, W J Jusko.   

Abstract

Finasteride is a 4-azasteroid inhibitor of one isoenzyme of 5 alpha-reductases that converts testosterone to dihydrotestosterone (DHT). We characterized the time course of DHT concentrations. The following model was used to assess DHT pharmacodynamics: [formula: see text] where joint fitting of three dose levels yielded kin0 = 28% change/hour, kout = 0.28 hour-1, IC50 = 0.012 ng/ml, and Emax = 0.7. The modification of a previous model with the maximum partial effect factor, Emax, may be useful in characterizing the pharmacodynamics of drugs with similar indirect mechanisms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479205

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  5 in total

Review 1.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.

Authors:  A Sharma; W J Jusko
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

2.  Characterization of four basic models of indirect pharmacodynamic responses.

Authors:  A Sharma; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

Review 3.  Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

4.  A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.

Authors:  Marta Valle; Enrico Di Salle; Maria Gabriella Jannuzzo; Italo Poggesi; Maurizio Rocchetti; Riccardo Spinelli; Davide Verotta
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics and pharmacodynamics of finasteride.

Authors:  J F Steiner
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.